Portal de investigación
Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Clausen J.
- Pérez Simón J.A.
- Carré M.
- Castilla-Llorente C.
- Michonneau D.
- Schauwvlieghe A.
- François S.
- Gabellier L.
- Corral L.L.
- Benzaquén A.
- Labussière-Wallet H.
- Cornillon J.
- Devillier R.
- Huynh A.
- Turlure P.
- Bauhofer A.
- Jullien de Pommerol H.
- Bruelle M.
- Faghmous I.
- Masouleh B.K.
- Plantamura E.
- Malard F.
- Mohty M.
Grupos
Abstract
CHRONOS is a multicenter, retrospective, cohort study involving acute graft-versus-host disease (aGvHD) adult patients with gastrointestinal (GI) symptoms, steroid- and ruxolitinib refractory, who initiated third-line therapy between 30 May 2019 and 30 September 2024. Primary endpoints were all-organ overall response rate (ORR) and GI-specific ORR (GI-ORR) around 28 days after treatment initiation. Secondary endpoints included duration of response, real-world progression-free survival (rwPFS) of underlying malignancy, and overall survival (OS). Fifty-nine patients from 16 sites in Europe were included. On Day 28, ORR was 36% (95% CI: 24–49%), GI-ORR was 37% (95% CI: 25–51%); 29% (95% CI: 11–49%) of responders lost response within 30 days, and 52% (95% CI: 29–72%) within 90 days. Median rwPFS and median OS were both 86 days (95% CI: 54–128 days). Median OS was higher in responders than in non-responders (186 versus 45 days). Over the 12-month follow-up period, 41 patients died, mainly due to aGvHD progression (n = 25), and infectious complications (n = 9). Within 3 months, Grade = 2 infectious events occurred in 51% of patients; Grade 3–4 thrombocytopenia and neutropenia in 64% and 32%, respectively. These findings demonstrate limited effectiveness of third-line therapy in this cohort of steroid- and ruxolitinib-refractory aGvHD patients with GI symptoms. © The Author(s), under exclusive licence to Springer Nature Limited 2026.
Datos de la publicación
- ISSN/ISSNe:
- 0268-3369, 1476-5365
- Tipo:
- Article
- Páginas:
- 577-583
- PubMed:
- 41904242
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,998 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
BONE MARROW TRANSPLANTATION SPRINGERNATURE
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- Adult; Aged; Female; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Male; Middle Aged; Nitriles; Pyrazoles; Pyrimidines; Retrospective Studies; Steroids; Treatment Outcome; alemtuzumab; corticosteroid; cyclophosphamide; etanercept; infliximab; inolimomab; leukocyte antigen; methotrexate; mycophenolic acid; ruxolitinib; steroid; teduglutide; thymocyte antibody; vedolizumab; nitrile; pyrazole derivative; pyrimidine derivative; ruxolitinib; steroid; acute graft versus host disease; acute lymphoblastic leukemia; acute myeloid leukemia; adult; Article; bacteremia; chronic myeloid leukemia; chronic myelomonocytic leukemia; clinical outcome; cohort analysis; female; follow up; gastrointestinal discomfort; hematopoietic cell; human; infection; major clinical study; male; mesenchymal stem cell; middle aged; mortality; multicenter study; myelodysplastic syndrome; myelofibrosis; myeloproliferative neoplasm; neutropenia; non-Hodgkin lymphoma; overall response rate; overall survival; pho
Cita
Clausen J,Pérez JA,Carré M,Castilla C,Michonneau D,Schauwvlieghe A,ASENSI P,François S,Gabellier L,Corral LL,Benzaquén A,Labussière H,Cornillon J,Devillier R,Huynh A,Turlure P,Bauhofer A,Jullien de Pommerol H,Bruelle M,Faghmous I,Masouleh BK,Plantamura E,Malard F,Mohty M. Clinical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure. Bone Marrow Transplant. 2026. 61. (5):p. 577-583. IF:5,100. (1).